ARD-266 - Moligand™ , Antagonist of Androgen receptor, CAS No.A607717, Antagonist of Androgen receptor

CAS: A607717 Cat. No.: A607717 PubChem CID: 145996519

GRADE & PURITY Moligand™

Synonyms

compound 11

Storage

Room temperature

Application

PROTAC

Specifications

Synonyms

compound 11

Specifications & Purity

Moligand™

Storage

Room temperature

Grade

Moligand™

Action Type

ANTAGONIST

Mechanism of action

Antagonist of Androgen receptor

Names and Identifiers

Canonical Smiles

N#Cc1ccc(cc1Cl)O[C@@H]1C(C)(C)[C@H](C1(C)C)NC(=O)c1ccc(cc1)C#CC1CCN(CC1)C(=O)C[C@@H](c1ccccc1)NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](c1onc(c1)C)C(C)C)O

IUPAC Name

(2S,4R)-N-((S)-3-(3-(4-((4-(((1r,3r)-3-(3-Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)ethynyl)piperidin-1-yl)azetidin-1-yl)-3-oxo-1-phenylpropyl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide

InChIKey

RTNONCBKGZNCJS-LJLQSONVSA-N

INCHI

1S/C52H59ClN6O7/c1-31(2)45(43-25-32(3)57-66-43)48(64)59-30-38(60)26-42(59)47(63)55-41(35-11-9-8-10-12-35)28-44(61)58-23-21-34(22-24-58)14-13-33-15-17-36(18-16-33)46(62)56-49-51(4,5)50(52(49,6)7)65-39-20-19-37(29-54)40(53)27-39/h8-12,15-20,25,27,31,34,38,41-42,45,49-50,60H,21-24,26,28,30H2,1-7H3,(H,55,63)(H,56,62)/t38-,41+,42+,45-,49-,50-/m1/s1

Isomeric SMILES

CC1=NOC(=C1)[C@@H](C(C)C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC(=O)N3CCC(CC3)C#CC4=CC=C(C=C4)C(=O)NC5C(C(C5(C)C)OC6=CC(=C(C=C6)C#N)Cl)(C)C)C7=CC=CC=C7)O

PubChem CID

145996519

Associated Targets(Human)

AR Tclin Androgen receptor (0 Activities)

Discover Target: AR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

LNCaP (8286 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

VCaP (1078 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Application Protocols

No vendor-tested application protocols are provided for this item.

General protocols for small-molecule screening materials (for research use only):

• Stock preparation: Dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate briefly. Filter through 0.2 µm PTFE if particulates persist.
• Aliquoting: Dispense into low-bind tubes or 96/384-well plates under dry, inert conditions when possible. Seal to prevent evaporation and water uptake.
• Working solutions: Dilute into assay buffer or media to achieve desired final concentration, keeping DMSO ≤0.5–1% unless otherwise validated.
• Documentation: Record lot number, preparation date, concentration, and storage conditions. Verify concentration by weight-in or quantitative NMR when potency metrics are critical.

These are general best practices and are not item-specific instructions. Always adapt to your assay system and consult the SDS.

Biological Roles

Item-specific biological targets, pathways, or mechanisms are not provided in the product data.

• Target, mode of action, and pathway mapping: Not specified for this item; refer to CoA/Spec Sheet or internal assay data.
• Biological role classification: As a Moligand screening compound, ARD-266 would typically be used as a putative ligand or probe candidate during hit discovery and SAR exploration.

General best practices when biological function is unknown:

• Perform target deconvolution (e.g., thermal shift profiling, chemoproteomics, genetic sensitivity) after observing phenotypic or biochemical activity.
• Evaluate aggregation, redox cycling, and non-specific membrane disruption to rule out assay artifacts.
• Establish basic ADME-relevant properties experimentally (solubility at assay pH, chemical stability, permeability in PAMPA or cell-based surrogates) before interpreting potency data.

Caveat: No claims are made regarding biological efficacy, safety, or therapeutic use. For research use only.

Buffer Applications

This product is a small-molecule screening compound, not a buffering agent. No item-specific buffer system applicability is provided.

Practical notes for buffer handling with small-molecule ligands:

• Dissolve first in DMSO to make a concentrated stock; then dilute into assay buffer (e.g., PBS, HEPES, or Tris) under vigorous mixing to minimize precipitation.
• Maintain final DMSO ≤0.5–1% v/v unless the assay specifically tolerates higher levels.
• If precipitation persists, add compatible excipients (e.g., 0.01–0.05% non-ionic surfactant) or increase ionic strength modestly. Validate that any additives do not interfere with the assay.

No specific buffer recipes or pH ranges are associated with ARD-266 in the provided data.

Green Alternatives

Green chemistry considerations are generally tied to solvent/reagent selection. As ARD-266 is a screening ligand rather than a process solvent or reagent, “green alternative” discussions focus on handling and solvent choices.

Greener handling approaches (general guidance):

• Use minimal DMSO volumes for stocks and prefer aqueous buffers for dilutions to reduce VOC use.
• For LC–MS/analytical work, prefer acetonitrile–water over chlorinated eluents when feasible.
• If synthesis or reformatting is conducted, apply solvent selection guides (e.g., switch from DMF/NMP to safer alternatives where solubility permits).

Comparison (general):

• DMSO: Broadly accepted in bioassays; low volatility; relatively benign compared with DMF/NMP but can carry solutes through skin—use gloves.
• Ethanol/isopropanol: Greener than acetonitrile for some tasks but may impact bioassays; evaluate case-by-case.

Note: No process-scale usage is anticipated for this item. Lifecycle impacts are primarily from small-volume organic solvent use during dissolution, aliquoting, and analysis. Implement microplate-based, low-volume workflows to minimize waste.

Pharmaceutical Uses

No pharmacopeial status, excipient roles, or formulation applications are specified for ARD-266. This product is supplied strictly for research use only.

General R&D formulation context (non-clinical):

• For in vitro studies, prepare DMSO stocks and dilute into assay media as compatible.
• For exploratory in vivo research (if conducted under appropriate approvals), users typically develop bespoke vehicles (e.g., DMSO/PEG/Tween/saline systems) based on compound solubility and stability. Such uses are outside the scope of the supplied product information and must be qualified independently.

No claims are made regarding therapeutic use, safety, or clinical application.

Physical Properties

Item-specific physicochemical properties are not provided in the product data.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (literature/estimated): Not available; do not infer without structure.
• Boiling point (literature): Not available.
• Density (literature): Not available.
• LogP/logD, pKa, refractive index (literature/computed): Not available.
• Aqueous solubility: Not specified for this item; typical practice is to prepare DMSO stock then dilute into assay media with ≤1% DMSO final.

Practical guidance when physical data are unknown:

• Begin with a concentrated DMSO stock (e.g., 10–50 mM) if compatible with downstream assays; confirm solubility visually and by LC–UV.
• For buffer/solvent compatibility, test a small panel (DMSO, DMF, acetonitrile, methanol, ethanol, PBS + surfactant) to identify precipitation limits.
• If the compound is hydrophobic, use co-solvent approaches (DMSO ➝ aqueous buffer with 0.01–0.05% non-ionic surfactant) and gentle heating (≤40 °C) or brief sonication.
• Avoid assuming stability toward hydrolysis/oxidation; perform stability-indicating LC–MS at intended storage and assay conditions.

Note: Reported/guaranteed values must be taken from the CoA/Spec Sheet. Do not treat exploratory measurements as specifications.

Quality & Grades

• Grade/Purity: Moligand™ (product data). The Moligand designation identifies small-molecule ligands intended for discovery and screening workflows rather than commodity reagent grades.

What Moligand typically implies (general guidance):

• Emphasis on identity confirmation suitable for screening libraries (e.g., LC–MS purity/identity checks). Exact acceptance criteria, residual solvent limits, water content, and metal/peroxide specifications are not stated here.
• UV transparency and low non-volatile residue are not guaranteed unless explicitly indicated.

Item-specific details:

• Assay purity, residual solvents, water content (Karl Fischer), metals, and stabilizers: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Recommendations for users:

• For biochemical/biophysical assays, request the latest CoA to confirm identity data (e.g., LC–MS, NMR as available) and purity thresholds.
• For analytical method development, obtain any available reference spectra and impurity profiles.
• If the program requires enhanced analytical or HPLC grade attributes (e.g., low UV cut-off solvents or trace metal control), verify suitability before use or perform in-house qualification.

Reaction & Applications

This product is positioned as a Moligand small-molecule ligand for research and screening. It is not primarily offered as a synthetic reagent or solvent.

• Synthetic reaction usage (Grignard, cross-coupling, etc.): Not typically applicable for this item due to unknown structure and intended use as a screening compound.
• Recommended applications (per category): Small-molecule and compound library research, hit finding, and exploratory SAR once a target is identified in-house.

Practical guidance for discovery workflows:

• Prepare DMSO stocks under dry conditions; filter (0.2 µm PTFE) if particulate is observed. Record concentration by weight-in or via quantitative NMR against an internal standard when exact potency is required.
• Establish stability in common assay media (e.g., PBS, HEPES, cell culture medium) over the intended incubation time using LC–MS to monitor degradation and adsorption to plastics.
• Avoid repeated freeze–thaw of DMSO stocks; aliquot to single-use vials.

If chemical reactivity is a concern (PAINS or covalent binders):

• Without structure, reactivity cannot be assessed. Perform orthogonal counterscreens (thiol reactivity, redox cycling, detergent sensitivity) as a best practice for novel ligands.

Manufacturer applications: Not specified beyond category listing; no specific biological target or assay guidance is provided in the product data.

Reaction Conditions

Not typically applicable. ARD-266 is not supplied as a reagent for chemical synthesis, and no reaction condition data are provided.

General analytical and handling conditions for screening compounds:

• LC–MS: Start with water/acetonitrile (0.1% formic acid) gradients; explore methanol if ionization or solubility is poor. Column: C18, 2.1 mm ID, 1.7–3 µm, 30–40 °C. These are general literature practices, not item specifications.
• Solid handling: If solid, weigh quickly to minimize atmospheric moisture uptake; if oil, use positive displacement pipettes.
• Stability checks: Incubate at intended assay temps (e.g., 25–37 °C) and monitor for degradation over time by LC–UV/MS.

No temperature, catalyst, or yield data are available or applicable to this item.

Safety & Handling

Hazard communication details are not provided in the product data. Always consult the product SDS for authoritative safety information.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.

General laboratory precautions for small-molecule research compounds:

• PPE: Lab coat, nitrile gloves, and splash-protection eyewear. Use a certified chemical fume hood to avoid inhalation of dusts, aerosols, or solvent vapors.
• Avoid ingestion, inhalation, and skin/eye contact. Wash thoroughly after handling.
• Storage incompatibilities: Until structure is confirmed, segregate from strong oxidizers and acids/bases; keep dry and away from light if photolability is suspected. Follow “store tightly closed at room temperature” as per product data.
• Spill/accidental release: Absorb with inert material, avoid dust formation, and collect for disposal as hazardous chemical waste.
• First aid (overview; defer to SDS): If inhaled—fresh air; if on skin—wash with soap/water; if in eyes—rinse with water for several minutes; if ingested—rinse mouth, seek medical advice.
• Waste disposal: Dispose according to local regulations; treat as organic chemical waste. Do not discharge to drains.

Note: Some screening ligands may present unknown toxicological profiles. Handle on a small scale and minimize exposure.

Solvent Selection

Because the structure and polarity of ARD-266 are not disclosed here, select solvents empirically with emphasis on assay compatibility.

General strategy for small-molecule screening compounds:

• Primary stock solvent: DMSO is the default due to broad solvating power and assay compatibility at ≤1% v/v final concentration.
• Co-solvents: DMF and NMP improve solubility for highly lipophilic compounds but may be less assay-friendly; use sparingly.
• Protic/polar solvents: Methanol, ethanol, and isopropanol can aid dissolution and sterile filtration but may affect some bioassays.
• Aqueous buffers: After DMSO dissolution, dilute into PBS or assay buffer gradually while vortexing to avoid precipitation; add 0.01–0.05% non-ionic surfactant if needed.

Miscibility/handling notes (general):

• DMSO is fully miscible with water and most organics; confirm that the final DMSO concentration does not exceed assay tolerance.
• For LC–MS method development, acetonitrile/water with 0.1% formic acid is a common starting point; methanol may improve solubility for some analytes.

When to choose alternatives:

• If precipitation occurs upon aqueous dilution, increase DMSO seed percentage (e.g., from 0.1% to 0.5–1%), warm to 30–37 °C briefly, or include solubilizing excipients (cyclodextrins, tween-20 at low ppm levels) as assay-permitted.

Note: No item-specific solubility, logP, or pKa data are available for ARD-266 in the product data.

Storage & Reconstitution

• Storage conditions (product data): Room temperature.
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General best practices for small-molecule ligands:

• Keep container tightly closed in a dry place. Protect from excessive heat and direct light until stability is confirmed.
• If hygroscopic or photosensitive behavior is suspected, store in desiccator or amber vial, respectively. Confirm with supplier data when available.

Reconstitution (general guidance):

• Solvent: Anhydrous DMSO is recommended as a primary solvent for stock solutions unless otherwise specified.
• Typical stock concentrations: 10–50 mM (user defined). Verify complete dissolution visually and by analytical means if critical.
• Aliquot to single-use portions to avoid repeated freeze–thaw; if frozen, store at −20 to −80 °C per internal SOPs after confirming DMSO stock stability.
• Thawing: Warm to room temperature and vortex before use. Inspect for precipitation or discoloration; discard if degradation is suspected.

Note: Any guaranteed stability/shelf-life or re-test dates must be taken from the CoA/Spec Sheet. For research use only.

Structure & Identity

Item-specific identifiers for this catalog entry are limited. Where unavailable, consult the CoA/Spec Sheet.

• Item name: ARD-266 (Moligand series)
• SKU: A607717
• CAS: Not specified for this item; refer to CoA/Spec Sheet.
• PubChem CID: 145996519 (product data)
• InChIKey: 325626 (as provided; note: typical InChIKeys are 27-character hashes. Verify on CoA/SDS.)
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general guidance):

• The structural class and functional groups are not disclosed in the provided product data. As a Moligand small molecule, ARD-266 is intended for screening/ligand discovery workflows rather than as a commodity reagent. If structural elucidation is required for method development (e.g., LC–MS), request the latest structural identifiers from the product documentation.

2D structure description (general note):

• Without SMILES/InChI, ring systems, heteroatoms, or stereochemical centers cannot be described. Do not assume aromaticity, ionizable groups, or H-bonding capacity without confirmed structure. Use experimental characterization (LC–MS, HRMS, NMR) after obtaining reference data from the CoA.

Synthetic Utility

ARD-266 is presented as a Moligand screening compound and is not positioned as a general synthetic reagent or building block.

• Functional groups and reactivity: Not specified for this item; without structure, no reliable predictions on nucleophilicity/electrophilicity, redox behavior, or protecting group strategies can be made.
• Named reactions: Not applicable in the absence of structural information.

Guidance if derivatization is desired (general):

• Obtain structural data and confirm accessible handles before planning analog synthesis.
• If using ARD-266 as a reference standard in SAR, secure analytical-grade characterization (NMR, HRMS, HPLC) and develop a robust route to analogs rather than modifying this lot directly.

Conclusion: Treat ARD-266 as a screening reference material. For synthetic applications, first acquire the definitive structure and reactivity profile from the CoA or supplier technical support.

Target Specificity

Target specificity data (e.g., named protein, pathway, binding epitope) are not provided for ARD-266.

• Antigen/target name: Not specified for this item; refer to CoA/Spec Sheet.
• Assay-validated selectivity: Not specified.
• Off-target profile: Not specified.

Note: As a Moligand screening compound, specificity must be established by the end user through appropriate biochemical and orthogonal assays.